Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10959445 | 0.96 | RAB9A (0.63) | RAB9AMAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL3996600 | 0.92 | RAB9A (0.64) | RAB9AMAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL8488827 | 0.86 | RAB9A (0.62) | RAB9AMAPTSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL28609095 | 0.82 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL30020898 | 0.82 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL9337119 | 0.82 | RAB9A (0.68) | RAB9AMAPTSMN1; SMN2HPGDKMT2A | |
| SCHEMBL1171584 | 0.81 | CA12 (0.61) | RAB9ASMN1; SMN2LMNAHPGD | |
| SCHEMBL14028449 | 0.81 | CHRNB2 (0.69) | MAPTLMNAHPGDKMT2ACHRNB2 | |
| SCHEMBL3977089 | 0.80 | CHRNB2 (0.64) | MAPTLMNAHPGDKMT2ACHRNB2 | |
| SCHEMBL1999435 | 0.79 | RAB9A (0.90) | RAB9AMAPTSMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| EP-1530574-B1 | MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | SCHERING AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| EP-1530574-A1 | MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-18 | — | — | EP | disclosed |
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | SCHERING AG (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004026881-A1 | MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | CCNK, CDK2, CDK1 | RAB9A 2889/4885MAPT 4065/4885SMN1; SMN2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.